A Global Perspective on Incidence and Regional Trends of Opioid Use Disorders From 1990 to 2021

Tiantian Tuo; Yupeng Chen; Danyang Wang; Jinna Liu; Yujiao Wu; Jiawen Wang

doi:10.30773/pi.2025.0039

Psychiatry Investig > Volume 22(6); 2025 > Article

Tuo, Chen, Wang, Liu, Wu, and Wang: A Global Perspective on Incidence and Regional Trends of Opioid Use Disorders From 1990 to 2021

Original Article

Psychiatry Investigation 2025;22(6):668-677.

Published online: June 16, 2025

DOI: https://doi.org/10.30773/pi.2025.0039

A Global Perspective on Incidence and Regional Trends of Opioid Use Disorders From 1990 to 2021

Tiantian Tuo^1,^*

, Yupeng Chen^2,^*

, Danyang Wang³

, Jinna Liu¹

, Yujiao Wu⁴

, Jiawen Wang²

¹School of Pharmaceutical and Chemical Engineering, Yangling Vocational and Technical College, Yangling, China

²Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China

³Xi’an Medical University, Xi’an, China

⁴Department of Pharmacy, Changzhou Third People’s Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, China

Correspondence: Jiawen Wang, MD, PhD Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, No. 134 Dongjie Street, Gulou District, Fuzhou 350001, China Tel: +86-591-87557768, E-mail: 1811210684@pku.edu.cn

Correspondence: Yujiao Wu, MSc Department of Pharmacy, Changzhou Third People’s Hospital, Changzhou Medical Center, Nanjing Medical University, No. 300 Lanling Road, Tianning District, Changzhou 213003, China Tel: +86-519-82009980, E-mail: ctzs567@163.com

^* These authors contributed equally to this work.

Received February 6, 2025 Revised March 22, 2025 Accepted April 8, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective

Opioid use disorders (OUDs) have become a significant global public health challenge. Despite extensive research on the opioid crisis, the trends in incidence and regional disparities remain inadequately understood.

Methods

Data were obtained from the Global Burden of Disease 2021, covering 204 countries and territories. OUDs incidence cases and rates per 100,000 population were analyzed over the study period. Trends were evaluated using the estimated annual percentage change (EAPC).

Results

Globally, OUDs cases increased by 49.25% from 1,301,551 (95% uncertainty interval [UI]: 1,077,634 to 1,598,053) in 1990 to 1,942,525 (95% UI: 1,643,342 to 2,328,363) in 2021. The incidence rate in 2021 was 24.62 per 100,000 population, with an EAPC of -0.25 (95% confidence interval: -0.39 to -0.1). Males had slightly higher rates than females (25.39 vs. 23.84 per 100,000). Individuals aged 15-49 years carried the highest burden, while older age groups showed the largest increases in cases. High-income North America reported the highest incidence rate in 2021 (123.28 per 100,000) and the largest case increase (425.34%). Among countries, the United States had the highest incidence rate increase (EAPC: 5.55), while Switzerland experienced the largest decline (EAPC: -4.33). A moderate positive correlation was identified between 2021 incidence rates and socio-demographic development (ρ=0.382, p<0.001).

Conclusion

This study highlights substantial global variability in OUDs trends, with significant differences across regions, sexes, age groups, and countries. Findings emphasize the need for tailored prevention and treatment strategies.

Keywords: Opioid use disorders, Incidence, Global burden of disease, Public health

INTRODUCTION

Opioid use disorders (OUDs) have become one of the most challenging public health issues of the modern era, with profound impacts on individuals, families, and healthcare systems [1]. Despite significant advances in understanding the dynamics of the opioid crisis, the nature and scope of the epidemic continue to evolve, with shifting patterns of opioid misuse and varying regional responses [2]. As a result, there is a pressing need for continued research into the incidence and regional trends of OUDs to inform more effective prevention, treatment, and policy strategies [3].

Recent studies have documented the significant role of both prescription and illicit opioids in the progression of OUDs [4]. Research has highlighted how aggressive marketing and overprescribing in the late 20th and early 21st centuries contributed to the widespread misuse of prescription opioids [5]. As a response, many countries have implemented stricter opioid prescribing guidelines, which have led to a decrease in prescription opioid misuse in some regions [5,6]. However, this shift has often been accompanied by increased use of illicit opioids, particularly heroin and synthetic opioids like fentanyl, posing new challenges in regions with strict prescribing regulations [7].

Given the dynamic and multifactorial nature of the opioid epidemic, this study is crucial for gaining a deeper understanding of the global trends in OUDs and the regional factors that influence them. Therefore, this article provides a comprehensive investigation and analysis of the incidence of OUDs from 1990 to 2021, reviewing the potential influencing factors of global epidemiological trends through a retrospective analysis of large-scale epidemiological data from this period.

METHODS

Data collection and sources

This study utilized data from the Global Burden of Disease (GBD) 2021, which was accessed through the Global Health Data Exchange Query Tool [8]. The GBD 2021 dataset includes comprehensive information from 204 countries and 21 regions, covering the period from 1990 to 2021 [9]. These 21 regional groupings were selected based on geographical proximity and shared epidemiological features [8,9]. The data were categorized by year, sex, and age group, allowing for an in-depth examination of trends in OUDs incidence across various demographic groups. In addition, countries and regions were classified by their Socio-Demographic Index (SDI) into low, middle, and high SDI categories. This classification helped explore the relationship between socio-economic development levels and the prevalence of OUDs [10].

Disease definition

OUDs are defined as a maladaptive pattern of opioid use leading to clinically significant impairment or distress, including symptoms of dependence such as tolerance and withdrawal [7]. OUDs are a substance-related disorder characterized by dysfunctional opioid use patterns [3]. Cases included in the study must meet the diagnostic criteria for opioid dependence as defined by either the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (code: 304.00) or the ICD-10 (code: F11.2), with the exclusion of cases where opioid dependence is due to a general medical condition [11]. According to DSM-IV-TR, a diagnosis of opioid dependence requires at least three of the following symptoms within a 12-month period [12,13]: tolerance (need for increased amounts or diminished effect with continued use), withdrawal (symptoms or use of similar substances to avoid withdrawal), using progressively larger amounts or for longer periods than intended, unsuccessful efforts to reduce use, excessive time spent obtaining the substance; giving up important activities due to use, and continued use despite physical or psychological problems caused by it [14].

Statistical analysis

This study aimed to assess the global burden of OUDs across various regions and countries from 1990 to 2021, incorporating a 95% uncertainty interval (UI) for each parameter. Incidence rates, standardized per 100,000 population, were used as the basis for analysis, while estimated annual percentage changes (EAPC) were calculated to examine trends over time [15]. A joint regression model was employed to assess the disease burden, with the EAPC derived using a logarithmic linear regression approach. Detailed calculations for the EAPC are provided in previous studies [16,17]. An increase in burden was indicated when the lower limit of the EAPC and its 95% confidence interval (CI) exceeded zero, while a decrease was indicated when the upper limit and 95% CI fell below zero. The EAPC was calculated using the formula [16]:

y=α+βx+ε: EAPC=(eβ-1)×100%.

Pearson correlation analysis was performed to explore the relationship between the EAPC and OUDs incidence rates. Correlation coefficients (ρ) and p-values were used to assess the strength and significance of these associations.

Ethical approval

This study was approved by the Fuzhou University Affiliated Provincial Hospital in line with the Declaration of Helsinki (approval ref: 20241101). As a result of the secondary data analysis in this study, the review board waived informed consent. Additionally, this article does not contain any personal information about patients. All authors are in agreement with the manuscript.

RESULTS

Global patterns in OUDs

Globally, the incidence of OUDs showed a significant increase in the number of cases from 1990 to 2021, rising from 1,301,551 (95% UI: 1,077,634 to 1,598,053) in 1990 to 1,942,525 (95% UI: 1,643,342 to 2,328,363) in 2021, representing a 49.25% increase. However, the incidence rate remained relatively stable during this period, with a slight decline from 24.4 (95% UI: 20.2 to 29.96) per 100,000 population in 1990 to 24.62 (95% UI: 20.82 to 29.51) per 100,000 population in 2021, as indicated by an EAPC of -0.25 (95% CI: -0.39 to -0.1) (Table 1).

Sex-specific trends showed that while both males and females experienced increases in the number of cases, the EAPC for the incidence rate showed minor declines for males (-0.25, 95% CI: -0.46 to -0.05) and females (-0.23, 95% CI: -0.35 to -0.12). In 2021, males had slightly higher incidence rates at 25.39 (95% UI: 21.62 to 30.07) per 100,000 population compared to females at 23.84 (95% UI: 20.06 to 28.9) per 100,000 population (Figure 1A, B and Table 1). These findings underline the persistent burden of OUDs globally, with EAPC analyses revealing consistent trends across sexes, highlighting the need for continued focus on effective prevention and intervention strategies.

Age-group variations in OUDs

Age-specific analysis revealed notable differences in the trends of OUD incidence across age groups [18]. The highest burden was consistently observed among individuals aged 15-49 years, with the number of cases increasing from 1,177,122 (95% UI: 947,146 to 1,464,831) in 1990 to 1,722,800 (95% UI: 1,431,425 to 2,092,539) in 2021, although the incidence rate remained relatively stable during the study period, as indicated by an EAPC of -0.29 (95% CI: -0.45 to -0.13). In contrast, individuals aged 50-74 years saw a substantial 71.34% increase in the number of cases (95% CI: 63 to 80), accompanied by a decline in the incidence rate (EAPC: -0.84, 95% CI: -0.9 to -0.79). The most pronounced growth was observed in the 75+ years age group, where the number of cases rose by 122.88% (95% CI: 104 to 149), despite a concurrent decline in the incidence rate, as reflected by an EAPC of -0.64 (95% CI: -0.74 to -0.53) (Figure 1C, D and Table 1). These findings emphasize the persistent high burden of OUDs among individuals aged 15-49 years, while also drawing attention to the growing absolute number of cases in older age groups.

Regional variability in OUDs

From 1990 to 2021, the number of cases increased most significantly in the high SDI and low SDI regions. In high SDI regions, cases rose from 207,664 (95% UI: 173,326 to 252,999) in 1990 to 609,681 (95% UI: 518,566 to 721,842) in 2021, reflecting a 193.59% increase and accompanied by an EAPC of 2.97 (95% CI: 2.63 to 3.3). Similarly, low SDI regions experienced substantial growth, with cases rising from 60,715 (95% UI: 48,592 to 77,001) in 1990 to 155,170 (95% UI: 124,663 to 194,320) in 2021, representing a 155.57% increase. In terms of incidence rates, high SDI regions had the highest incidence in 2021 at 55.73 per 100,000 population (95% UI: 47.4 to 65.98). In contrast, high-middle and middle SDI regions exhibited declines over the study period, with EAPCs of -1.68 (95% CI: -2.14 to -1.22) and -1.33 (95% CI: -1.48 to -1.18), respectively (Figure 2A, B and Table 1).

Geographically, significant variability was observed, with regions like high-income North America and Eastern Europe reporting the highest incidence rates in 2021. High-income North America had the highest global incidence rate at 123.28 (95% UI: 103.38 to 148.55) per 100,000 population, reflecting the most substantial regional burden, alongside a remarkable increase in cases by 425.34% (95% CI: 370 to 488). Similarly, Eastern Europe exhibited a high incidence rate of 62.48 (95% UI: 53.28 to 74.26) per 100,000 population, although this region experienced a decline in cases over time, with an EAPC of -0.85 (95% CI: -1.67 to -0.01). In contrast, East Asia recorded the sharpest reduction in incidence rates, declining from 34.49 (95% UI: 28.59 to 42.34) per 100,000 in 1990 to 16.64 (95% UI: 13.78 to 19.93) in 2021, with an EAPC of -3.02 (95% CI: -3.29 to -2.76) (Figure 2C and Table 1). Notably, males consistently exhibited higher incidence rates of OUDs compared to females across all SDI regions and geographic locations in 2021 (Figure 2C). High SDI and low SDI regions both demonstrated a growing number of cases, albeit with differing trends in incidence rates, while regions like high-income North America and Eastern Europe continue to bear disproportionately high burdens.

Country-specific differences in OUDs

From 1990 to 2021, countries exhibited notable variability in the trends of OUDs, reflected in changes in the number of cases, incidence rates, and EAPC values. The United States and Yemen experienced the largest increases in case numbers, with the United States rising by 472.25% (95% CI: 408.32 to 551.68) from 76,035.22 (95% UI: 62,125.89 to 95,104.29) in 1990 to 435,113.45 (95% UI: 362,566.92 to 528,377.7) in 2021, and Yemen increasing by 233.45% (95% CI: 189.66 to 274.92). In contrast, Switzerland and Italy demonstrated the most significant reductions, with Switzerland’s cases dropping by 60.48% (95% CI: -66.52 to -53.59) and Italy’s by 54.9% (95% CI: -60.22 to -48.51) (Figure 3A and Supplementary Table 1).

Incidence rates also varied widely across countries. The United States and Estonia reported the highest incidence rates in 2021, at 130.8 (95% UI: 109 to 158.84) and 118.5 (95% UI: 99.8 to 138.43) per 100,000 population, respectively, highlighting significant public health burdens. In contrast, Cook Islands and Tokelau recorded the lowest incidence rates, at 12.95 (95% UI: 10.68 to 15.75) and 13.79 (95% UI: 11.39 to 16.6) per 100,000 population, respectively (Figure 3B and Supplementary Table 1). In terms of trends, the United States and Sweden exhibited the fastest increases in incidence rates, with EAPCs of 5.55 (95% CI: 4.99 to 6.12) and 4.55 (95% CI: 4.32 to 4.78), respectively. On the other hand, Switzerland and Italy experienced notable declines, with EAPCs of -4.33 (95% CI: -4.69 to -3.96) and -3.43 (95% CI: -3.69 to -3.17), respectively (Supplementary Table 1). These disparities underscore the heterogeneous burden and dynamics of OUDs across countries.

Analysis of correlations in OUDs trends

The analysis of correlations in OUDs trends revealed notable patterns linking historical incidence rates, socio-demographic development, and disease burden. A weak but statistically significant negative correlation was found between EAPC and incidence rates in 1990 (ρ=-0.178, p=0.015), indicating that countries with higher baseline incidence rates in 1990 tended to experience slower growth or declines in incidence trends over time (Figure 4A). In contrast, there was no significant correlation observed between EAPC and the SDI in 2021 (ρ=-0.106, p=0.151), suggesting that socio-demographic factors alone may not fully explain changes in OUD incidence trends across countries (Figure 4B). However, a moderate positive correlation (ρ=0.382, p<0.001) was identified between incidence rates per 100,000 population and SDI in 2021, indicating that higher SDI levels were associated with higher OUD incidence rates (Figure 4C). This relationship highlights the disproportionate burden faced by countries with advanced socio-demographic development, such as the United States and Estonia, which exhibited significantly elevated incidence rates compared to other regions. These findings underscore the intricate interplay between historical burden, socio-demographic progress, and OUD trends, emphasizing the need for tailored interventions addressing both historical and current drivers of the disease.

DISCUSSION

The findings of this study provide a comprehensive analysis of global trends, regional variability, and country-specific differences in OUDs from 1990 to 2021, offering valuable insights into the evolving nature of the opioid epidemic. The global increase in the number of OUDs cases, despite a relatively stable incidence rate, reflects the impact of population growth and underscores the need for more effective strategies to reduce the burden of OUDs. The slight decline in incidence rates, as evidenced by the negative EAPC values, suggests some progress in managing the epidemic in certain regions; however, these declines have not been sufficient to offset the overall rise in case numbers. This finding aligns with previous research documenting the resilience of the opioid crisis and its capacity to adapt to shifting socio-demographic and regulatory contexts [18-21].

The persistent high burden among individuals aged 15-49 years emphasizes the critical need for targeted prevention and intervention efforts aimed at younger and middle-aged populations, who are most affected by the epidemic [22]. This demographic trend is consistent with earlier studies highlighting the intersection of OUDs with employment instability, social stressors, and co-occurring mental health disorders. Moreover, the substantial rise in the number of cases among older populations (75+ years) reflects an emerging challenge likely driven by long-term prescription opioid use, chronic pain management, and age-related vulnerabilities to substance misuse. These findings echo recent research that has identified the aging population as a growing contributor to the global burden of OUDs, particularly in high-income settings [21,23].

Significant geographic variability in OUDs trends further underscores the multifaceted nature of the epidemic. High-income North America, which exhibited the highest incidence rates and the most substantial increase in case numbers, highlights the entrenched nature of the opioid crisis in this region, as documented extensively in prior studies [24,25]. The United States, in particular, has experienced successive waves of opioid misuse, driven by prescription opioids, heroin, and, more recently, synthetic opioids such as fentanyl [26,27]. In contrast, regions such as Eastern Europe demonstrated a high burden but declining trends in OUDs incidence, which may reflect the impact of harm reduction strategies, improved treatment accessibility, or shifts in opioid availability and use patterns. These regional disparities align with previous research that has emphasized the importance of localized public health responses in addressing the opioid crisis [28].

At the country level, the stark differences in OUDs trends further illustrate the heterogeneity of the epidemic. Countries such as the United States and Estonia recorded the highest incidence rates in 2021, reflecting the challenges of balancing access to pain management with the risks of opioid misuse [24]. Conversely, countries like Switzerland and Italy demonstrated significant declines in OUD cases and incidence rates, potentially indicative of successful public health interventions, stricter regulatory controls, and the integration of harm reduction measures into healthcare systems. Sex differences also contribute to these variations, with socio-economic factors and behavioral differences playing a significant role. For example, males tend to have higher rates of opioid misuse due to various factors, including greater risk-taking behaviors and socio-cultural expectations surrounding masculinity. These findings reinforce the importance of evidence-based policies tailored to specific national contexts, addressing both gender and regional disparities, as highlighted in previous studies [29].

While this study offers valuable insights into the global and regional dynamics of OUDs, it is important to acknowledge certain limitations [14]. The reliance on modeled estimates from the GBD 2021 introduces some uncertainty, and variations in data quality across countries may affect the precision of the findings [30]. Furthermore, the analysis does not account for specific policy interventions or cultural factors that may have influenced OUDs trends in individual countries [31]. Despite these limitations, this study provides a robust foundation for understanding the global burden of OUDs and offers critical guidance for the development of targeted and effective public health strategies.

In conclusion, the findings of this study underscore the complex and evolving nature of the opioid epidemic, highlighting the urgent need for coordinated global efforts to address the burden of OUDs. By understanding the factors driving OUDs trends and regional disparities, policymakers and public health officials can develop tailored interventions to mitigate the devastating impact of the opioid crisis on individuals, families, and societies worldwide.

Supplementary Materials

The Supplement is available with this article at https://doi.org/10.30773/pi.2025.0039.

Supplementary Table 1.

Trends in the number of incidence cases and incidence rates of opioid use disorders in 204 countries from 1990 to 2021

pi-2025-0039-Supplementary-Table-1.pdf

Notes

Availability of Data and Material

The data are available from the Global Burden of Disease Results Tool of the Global Health Data Exchange (http://ghdx.healthdata.org/).

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Tiantian Tuo, Yupeng Chen, Danyang Wang. Data curation: Jinna Liu. Formal analysis: Jinna Liu. Investigation: Yujiao Wu, Jiawen Wang. Methodology: Tiantian Tuo, Yupeng Chen. Project administration: Tiantian Tuo, Yupeng Chen. Writing—original draft: Yujiao Wu, Jiawen Wang. Writing—review & editing: all authors.

Funding Statement

None

Acknowledgments

We would like to acknowledge the long-standing efforts of the Global Burden of Disease collaboration team in providing the valuable data and resources that made this study possible.

Figure 1.

Global burden of opioid use disorders. A: Number of opioid use disorder cases by sex from 1990 to 2021. B: Incidence rates of opioid use disorders by sex from 1990 to 2021. C: Total number of opioid use disorder cases across various age groups from 1990 to 2021. D: Incidence rates of opioid use disorders across different age categories from 1990 to 2021.

Figure 2.

Trends in opioid use disorder incidence by region. A: New cases of opioid use disorder in different SDI regions from 1990 to 2021. B: Incidence rates of opioid use disorders in various SDI regions from 1990 to 2021. C: Incidence rates of opioid use disorders in 2021 by sex, globally, and within SDI regions and geographical areas. SDI, Socio-Demographic Index.

Figure 3.

Geographic distribution of opioid use disorder incidence across 204 countries. A: Percentage change in the number of opioid use disorder cases between 1990 and 2021. B: Opioid use disorder incidence rates by country in 2021.

Figure 4.

Correlation between opioid use disorder incidence, EAPC, and SDI. A: Relationship between opioid use disorder incidence and EAPC in 1990. B: Link between the SDI and opioid use disorder incidence in 2021. C: Association between opioid use disorder incidence and SDI at the national level. SDI, Socio-Demographic Index; EAPC, estimated annual percentage change.

Table 1.

Global incidence rates and trends of opioid use disorders by sex, age, SDI regions, and geographic location from 1990 to 2021

Characteristics	Cases_1990	Rates_1990	Cases_2021	Rates_2021	Cases_change	EAPC_CI
Global	1,301,551 (1,077,634 to 1,598,053)	24.4 (20.2 to 29.96)	1,942,525 (1,643,342 to 2,328,363)	24.62 (20.82 to 29.51)	49.25 (43 to 57)	-0.25 (-0.39 to -0.1)
Sex
Male	662,004 (550,792 to 802,866)	24.65 (20.51 to 29.89)	1,005,215 (855,932 to 1,190,669)	25.39 (21.62 to 30.07)	51.84 (45 to 60)	-0.25 (-0.46 to -0.05)
Female	639,547 (526,910 to 793,022)	24.15 (19.9 to 29.95)	937,310 (788,734 to 1,136,322)	23.84 (20.06 to 28.9)	46.56 (40 to 54)	-0.23 (-0.35 to -0.12)
Age groups (yr)
15-49	1,177,122 (947,146 to 1,464,831)	43.43 (34.94 to 54.04)	1,722,800 (1,431,425 to 2,092,539)	43.63 (36.25 to 52.99)	46.36 (40 to 54)	-0.29 (-0.45 to -0.13)
50-74	111,749 (77,768 to 155,299)	14.58 (10.14 to 20.26)	191,466 (134,383 to 264,534)	11.66 (8.18 to 16.11)	71.34 (63 to 80)	-0.84 (-0.9 to -0.79)
75+	12,679 (8,140 to 18,201)	10.81 (6.94 to 15.51)	28,260 (19,822 to 37,616)	9.79 (6.87 to 13.04)	122.88 (104 to 149)	-0.64 (-0.74 to -0.53)
SDI regions
High SDI	207,664 (173,326 to 25,2999)	23.61 (19.71 to 28.77)	609,681 (518,566 to 721,842)	55.73 (47.4 to 65.98)	193.59 (171 to 221)	2.97 (2.63 to 3.3)
High-middle SDI	390,707 (326,323 to 47,7149)	36.74 (30.68 to 44.86)	335,810 (28,4831 to 398,899)	25.75 (21.84 to 30.59)	-14.05 (-20 to -8)	-1.68 (-2.14 to -1.22)
Middle SDI	450,751 (371,018 to 556,894)	26.16 (21.53 to 32.32)	469,928 (393,637 to 562,644)	19.19 (16.08 to 22.98)	4.25 (-2 to 11)	-1.33 (-1.48 to -1.18)
Low-middle SDI	190,951 (152,928 to 24,1535)	16.44 (13.17 to 20.8)	370,911 (305,809 to 455,798)	19.31 (15.92 to 23.73)	94.24 (86 to 105)	0.41 (0.32 to 0.5)
Low SDI	60,715 (48,592 to 77,001)	12.11 (9.69 to 15.36)	155,170 (124,663 to 194,320)	13.89 (11.16 to 17.39)	155.57 (148 to 164)	0.34 (0.29 to 0.39)
Location
Andean Latin America	6,715 (5,158 to 8,555)	17.67 (13.58 to 22.52)	12,380 (9,823 to 15,471)	18.72 (14.85 to 23.39)	84.37 (73 to 98)	0.28 (0.18 to 0.38)
Australasia	9,220 (7,965 to 1,0662)	45.47 (39.28 to 52.58)	12,977 (11,089 to 15,009)	41.91 (35.82 to 48.48)	40.75 (22 to 63)	-0.63 (-0.94 to -0.31)
Caribbean	6,948 (5,503 to 8,823)	19.69 (15.59 to 25)	7,627 (6,096 to 9,437)	16.07 (12.84 to 19.88)	9.77 (4 to 16)	-0.72 (-0.79 to -0.66)
Central Asia	25,909 (20,775 to 31,992)	37.38 (29.97 to 46.16)	35,075 (29,584 to 41,820)	36.61 (30.88 to 43.65)	35.38 (24 to 50)	0.13 (-0.17 to 0.43)
Central Europe	16,514 (13,678 to 19,962)	13.2 (10.93 to 15.96)	16,499 (14,141 to 19,429)	14.31 (12.27 to 16.86)	-0.09 (-6 to 9)	0.17 (0.06 to 0.27)
Central Latin America	27,557 (21,406 to 35,170)	16.76 (13.02 to 21.39)	40,991 (32,758 to 50,725)	16.2 (12.95 to 20.05)	48.75 (41 to 58)	-0.1 (-0.21 to 0)
Central Sub-Saharan Africa	5,589 (4,362 to 7,057)	10.17 (7.94 to 12.84)	16,045 (12,748 to 20,234)	11.72 (9.31 to 14.78)	187.1 (169 to 207)	0.52 (0.49 to 0.56)
East Asia	419,882 (348,059 to 51,5521)	34.49 (28.59 to 42.34)	244,998 (202,876 to 293,577)	16.64 (13.78 to 19.93)	-41.65 (-48 to -35)	-3.02 (-3.29 to -2.76)
Eastern Europe	152,974 (127,089 to 183,616)	67.54 (56.11 to 81.07)	129,175 (110,164 to 153,540)	62.48 (53.28 to 74.26)	-15.56 (-22 to -7)	-0.85 (-1.67 to -0.01)
Eastern Sub-Saharan Africa	17,387 (13,745 to 22,221)	9.11 (7.2 to 11.64)	42,755 (34,332 to 53,621)	10.03 (8.06 to 12.58)	145.9 (138 to 154)	0.18 (0.14 to 0.22)
High-income Asia Pacific	27,980 (22,476 to 34,512)	16.14 (12.96 to 19.91)	23,885 (194,34 to 28,719)	12.88 (10.48 to 15.49)	-14.64 (-20 to -9)	-0.81 (-0.92 to -0.71)
High-income North America	86,864 (71,332 to 108,021)	30.87 (25.35 to 38.39)	456,337 (382,680 to 549,886)	123.28 (103.38 to 148.55)	425.34 (370 to 488)	5.21 (4.65 to 5.78)
North Africa and Middle East	121,490 (94,834 to 154,340)	35.82 (27.96 to 45.5)	245,271 (203,638 to 296,380)	39.37 (32.69 to 47.57)	101.89 (86 to 119)	0.31 (0 to 0.62)
Oceania	767 (608 to 973)	11.71 (9.29 to 14.85)	1,737 (1,407 to 2,155)	12.47 (10.1 to 15.47)	126.42 (113 to 143)	0.26 (0.23 to 0.29)
South Asia	175,003 (140,846 to 221,257)	16.01 (12.88 to 20.24)	378,428 (309,715 to 466,046)	20.49 (16.77 to 25.24)	116.24 (108 to 125)	0.55 (0.32 to 0.78)
Southeast Asia	43,498 (34,656 to 53,759)	9.34 (7.44 to 11.55)	68,526 (56,761 to 82,427)	9.81 (8.13 to 11.8)	57.54 (48 to 70)	0.01 (-0.08 to 0.1)
Southern Latin America	8,960 (6,918 to 11,184)	18.09 (13.97 to 22.58)	12,389 (9,946 to 15,253)	18.3 (14.69 to 22.53)	38.28 (29 to 49)	-0.02 (-0.12 to 0.08)
Southern Sub-Saharan Africa	17,180 (14,051 to 21,388)	32.77 (26.81 to 40.8)	19,234 (16,064 to 23,406)	23.95 (20 to 29.15)	11.96 (6 to 19)	-1.31 (-1.72 to -0.9)
Tropical Latin America	27,857 (21,478 to 35,429)	18.26 (14.08 to 23.22)	37,570 (29,895 to 46,843)	16.51 (13.14 to 20.59)	34.87 (28 to 42)	-0.25 (-0.43 to -0.07)
Western Europe	84,153 (71,514 to 99,715)	21.89 (18.6 to 25.94)	90,782 (78,907 to 104,671)	20.76 (18.04 to 23.93)	7.88 (1 to 15)	-0.7 (-0.93 to -0.47)
Western Sub-Saharan Africa	19,106 (15,024 to 24,340)	9.89 (7.78 to 12.6)	49,843 (39,459 to 63,152)	10.18 (8.06 to 12.89)	160.87 (153 to 169)	0.05 (-0.01 to 0.11)

Data in parentheses are 95% uncertainty intervals for cases and rates and 95% CI for EAPC. SDI, Socio-Demographic Index; EAPC, estimated annual percentage change; CI, confidence interval

REFERENCES

1. Mehta S, Peterson H, Ye J, Ibrahim A, Saeed G, Linsky S, et al. Alterations in volume and intrinsic resting-state functional connectivity detected at brain MRI in individuals with opioid use disorder. Radiology 2024;313:e240514.

2. Luján MÁ, Young-Morrison R, Aroni S, Katona I, Melis M, Cheer JF. Dynamic overrepresentation of accumbal cues in food- and opioid-seeking rats after prenatal THC exposure. Sci Adv 2024;10:eadq5652

3. Gorfinkel LR, Malte CA, Fink DS, Mannes ZL, Wall MM, Olfson M, et al. Trends in opioid use disorder in the veterans health administration, 2005-2022. JAMA Netw Open 2024;7:e2451821.

4. Gaudreault PO, King SG, Huang Y, Ceceli AO, Kronberg G, Alia-Klein N, et al. Frontal white matter changes and craving recovery in inpatients with heroin use disorder. JAMA Netw Open 2024;7:e2451678.

5. Olding M, Rudzinski K, Schmidt R, Kolla G, German D, Sereda A, et al. Perspectives on diversion of medications from safer opioid supply programs. JAMA Netw Open 2024;7:e2451988.

6. Marino EN, Karns-Wright T, Perez MC, Potter JS. Smartphone app-based contingency management and opioid use disorder treatment outcomes. JAMA Netw Open 2024;7:e2448405.

7. Lapham GT, Hyun N, Bobb JF, Wartko PD, Matthews AG, Yu O, et al. Nurse care management of opioid use disorder treatment after 3 years: a secondary analysis of the PROUD cluster randomized clinical trial. JAMA Netw Open 2024;7:e2447447.

8. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021. Lancet 2024;403:2100-2132.

9. GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021. Lancet 2024;403:2162-2203.

10. Murray CJL, GBD 2021 Collaborators. Findings from the global burden of disease study 2021. Lancet 2024;403:2259-2262.

11. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021. Lancet 2024;403:2133-2161.

12. Compton WM, Einstein EB, Han B. 12-month prevalence estimates of substance use disorders using DSM-5 versus DSM-IV criteria among U.S. nonelderly adults with substance use. Am J Psychiatry 2024;181:1018-1021.

13. Hasin D, Stohl M. Higher prevalence estimates of substance use disorders with DSM-5 versus DSM-IV criteria among U.S. nonelderly adults with substance use: the role of DSM-IV diagnostic orphans. Am J Psychiatry 2024;181:955-957.

14. GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the global burden of disease study 2019. Lancet 2020;396:1160-1203.

15. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015;385:117-171.

16. Tang H, Zhang N, Liu X, Xiao H, Zhang H, Zhou K, et al. Incidence trends of inherited anemias at the global, regional, and national levels over three decades. J Epidemiol Glob Health 2024;14:72-85.

17. Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J 2023;13:82

18. Schol J, Huang IH, Carbone F, Fernandez LMB, Gourcerol G, Ho V, et al. Rome foundation and international neurogastroenterology and motility societies’consensus on idiopathic gastroparesis. Lancet Gastroenterol Hepatol 2025;10:68-81.

19. Tatara E, Ozik J, Pollack HA, Schneider JA, Friedman SR, Harawa NT, et al. Agent-based model of combined community- and jail-based take-home naloxone distribution. JAMA Netw Open 2024;7:e2448732.

20. Lindner S, Hart K, Manibusan B, Johnston KA, McCarty D, McConnell KJ. Effects of Medicaid waivers on use of medications for opioid use disorder and nonfatal overdoses in 17 states. Health Aff (Millwood) 2024;43:1597-1604.

21. Palis H, Hu K, Tu A, Scheuermeyer F, Staples JA, Moe J, et al. Chronic disease diagnoses and health service use among people who died of illicit drug toxicity in British Columbia, Canada. BMC Med 2024;22:479

22. Jiang Y, Li L. Projections of functional dependence among the late middle-aged and older population from 2018-2048 in China: a dynamic microsimulation. Glob Health Res Policy 2024;9:15

23. Gaither JR, McCollum S, Bechtel K, Leventhal JM, Mintz S. The circumstances surrounding fatal pediatric opioid poisonings, 2004-2020. Pediatrics 2024;154(Suppl 3):e2024067043N.

24. Dyer O. Opioid crisis: fall in US overdose deaths leaves experts scrambling for an explanation. BMJ 2024;386:q2091

25. Gezer F, Howard KA, Litwin AH, Martin NK, Rennert L. Identification of factors associated with opioid-related and hepatitis C virus-related hospitalisations at the ZIP code area level in the USA: an ecological and modelling study. Lancet Public Health 2024;9:e354-e364.

26. Connolly S, Terranella A, Guy GP Jr, Mikosz CA. Pattern of buprenorphine treatment retention among youth aged 10 to 18 years-US, 2015 to 2021. JAMA Pediatr 2024;178:940-942.

27. Chatterjee A, Stewart EA, Assoumou SA, Chrysanthopoulou SA, Zwick H, Harris RA, et al. Health and economic outcomes of offering buprenorphine in homeless shelters in Massachusetts. JAMA Netw Open 2024;7:e2437233.

28. Cantor J, Griffin BA, Levitan B, Mendon-Plasek SJ, Stein BD, Hunter SB, et al. Availability of medications for opioid use disorder in community mental health facilities. JAMA Netw Open 2024;7:e2417545.

29. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Psychiatry 2018;5:987-1012.

30. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet 2020;396:1204-1222.

31. Daryabor A, Akbarzadeh Baghban A. Comparison of a 30-year trend of incidence, prevalence, and DALY due to low back pain in Iran with low- and high-SDI countries; based on GBD study 2019 data. Arch Acad Emerg Med 2024;12:e39.